On 21 September 2026 the US FDA recorded a supplement to abbreviated new drug application 090779, a generic acetazolamide held by Indicus Pharma. The public record does not state what changed; supplements to generic applications usually concern manufacturing, packaging or labelling alignment.
This is not a new indication or a safety communication, and acetazolamide prescribing is unchanged. The action applies to the US market; CDSCO's position on this product is not stated.
- No change to acetazolamide use follows from this notice.
- Continue to check renal function, electrolytes and sulfonamide allergy before prescribing.
- Keep courses short where possible; paraesthesia and fatigue limit long-term use.
- Check the record for detail before telling patients anything has changed.
Why it matters
Routine generic licence actions should not prompt switching or concern.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free